Análises sanguíneas na deteção do cancro
Miniatura indisponível
Data
2023
Autores
Título da revista
ISSN da revista
Título do Volume
Editora
Resumo
O cancro é a sexta causa de morte a nível mundial representando uma forte ameaça socioeconómica afetando desta forma a qualidade de vida da população em geral. O mieloma múltiplo (MM) é um tipo de cancro para o qual apenas existe tratamento para prolongamento de vida. Relativamente à incidência compreende-se na idade adulta. Após deteção, a esperança média de vida varia de 5 a 10 anos.
A sua deteção faz-se através de vários meios complementares de diagnóstico focando-se essencialmente nos biomarcadores sanguíneos.
Os biomarcadores a serem abordados nesta dissertação irão focar-se num case study tendo sido recolhidos dados clínicos de janeiro de 2018 a abril de 2022. Serão então abordados os biomarcadores de hipercalcémia, insuficiência renal, anemia, lesões ósseas, Sistema de Estadiamento de Durie-Salmon (DSS), Sistema de Estadiamento Internacional (ISS), eletroforese de proteínas séricas, percentagem de plasmócitos, proteína de Bence-Jones na urina, Aspartato Aminotransferase (AST), Alanina Aminotransferase (AST), Gama-Glutamil Transpeptidase (GGT), ureia, ionograma e Imunoglobulina M (IgM).
Os dados recolhidos foram analisados em simultâneo com o tratamento farmacológico realizado neste intervalo de tempo. Foi feita uma análise e avaliação à eficácia do tratamento. Palavras-chave: Mieloma múltiplo, biomarcadores
Cancer is the sixth leading cause of death worldwide, representing a strong socioeconomic threat, thus affecting the quality of life of the general population. Multiple myeloma (MM) is a type of cancer for which there is only treatment to prolong life. Regarding the incidence, it is understood in adulthood. After detection, the average life expectancy ranges from 5 to 10 years. Its detection is done through several complementary diagnostic means, focusing essentially on blood biomarkers. The biomarkers to be addressed in this dissertation will focus on a case study, with clinical data collected from January 2018 to April 2022. Biomarkers of hypercalcemia, renal failure, anemia, bone lesions, Durie-Staging System will then be addressed. Salmon (DSS), International Staging System (ISS), serum protein electrophoresis, percentage of plasma cells, Bence-Jones protein in urine, Aspartate Aminotransferase (AST), Alanine Aminotransferase (AST), Gamma-Glutamyl Transpeptidase (GGT), urea, ionogram and Immunoglobulin M (IgM). The collected data were analyzed simultaneously with the pharmacological treatment carried out in this time interval. An analysis and evaluation of the effectiveness of the treatment was carried out. Keywords: Multiple myeloma, biomarkers
Cancer is the sixth leading cause of death worldwide, representing a strong socioeconomic threat, thus affecting the quality of life of the general population. Multiple myeloma (MM) is a type of cancer for which there is only treatment to prolong life. Regarding the incidence, it is understood in adulthood. After detection, the average life expectancy ranges from 5 to 10 years. Its detection is done through several complementary diagnostic means, focusing essentially on blood biomarkers. The biomarkers to be addressed in this dissertation will focus on a case study, with clinical data collected from January 2018 to April 2022. Biomarkers of hypercalcemia, renal failure, anemia, bone lesions, Durie-Staging System will then be addressed. Salmon (DSS), International Staging System (ISS), serum protein electrophoresis, percentage of plasma cells, Bence-Jones protein in urine, Aspartate Aminotransferase (AST), Alanine Aminotransferase (AST), Gamma-Glutamyl Transpeptidase (GGT), urea, ionogram and Immunoglobulin M (IgM). The collected data were analyzed simultaneously with the pharmacological treatment carried out in this time interval. An analysis and evaluation of the effectiveness of the treatment was carried out. Keywords: Multiple myeloma, biomarkers
Descrição
Orientação: Marisa Nicolai
Palavras-chave
MESTRADO INTEGRADO EM CIÊNCIAS FARMACÊUTICAS, CIÊNCIAS FARMACÊUTICAS, PHARMACEUTICAL SCIENCES, MIELOMA MÚLTIPLO, MULTIPLE MYELOMA, BIOMARCADORES, BIOMARKERS